Psoriasis
Immunology 1 original drugsImmunology indication. Psoriasis has 1 FDA-approved novel treatment, led by SHORLA, with 139 active industry clinical trials across 1 drug target. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Psoriasis Market Leaders
Companies with the most FDA-approved novel Psoriasis drugs.
Phase 3 Readouts Pro
12 active Phase 3 trials with confidence-graded completion dates.
Q4 2027
Total coumarin (TC) cream
Psoriasis Research Institute of Guangzhou
Estimated · aging NCT07426120
Unlock 9 more readouts with confidence-graded estimates
Upgrade to Pro Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Psoriasis Treatments by Mechanism
Top 12 mechanisms across 115 industry trials with a known mechanism of action.
Interleukin-23 Antagonist
13 trials 3 active 5 sponsors
Tyrosine Kinase 2 Inhibitor
7 trials 3 active 1 sponsor
Interleukin-17 Receptor A Antagonist
7 trials 1 active 2 sponsors
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
1 trials 1 active 1 sponsor
Sphingosine 1-phosphate Receptor Modulator
1 trials 1 active 1 sponsor
Interleukin-17A Antagonist
28 trials 3 sponsors
Phosphodiesterase 4 Inhibitor
16 trials 2 sponsors
Tumor Necrosis Factor Blocker
16 trials 7 sponsors
TNF
13 trials 6 sponsors
Interleukin-12 Antagonist
8 trials 7 sponsors
Folate Analog Metabolic Inhibitor
3 trials 3 sponsors
Aryl Hydrocarbon Receptor Agonist
2 trials 1 sponsor
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Psoriasis Clinical Pipeline by Phase
858 industry-sponsored trials across 235 sponsors
Showing 76 of 76 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Johnson & Johnson | Guselkumab | Interleukin-23 Antagonist [EPC] | RECRUITING | 2027-08-31 | NCT07654751 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | RECRUITING | 2028-05 | NCT06857942 |
| Bausch Health Americas, Inc. | Brodalumab | Interleukin-17 Receptor A Antagonist [EPC] | ACTIVE NOT RECRUITING | 2028-12 | NCT03240809 |
| Bausch Health Americas, Inc. | IDP-122 Lotion | — | ACTIVE NOT RECRUITING | 2026-11 | NCT03987763 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Vunakizumab (IL-17A inhibitor) | — | NOT YET RECRUITING | 2027-03 | NCT06779097 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Adalimumab Solution for Injection | — | NOT YET RECRUITING | 2028-04 | NCT07529925 |
| LEO Pharma | Spesolimab | — | COMPLETED | 2026-05-13 | NCT06013969 |
| AbbVie | Risankizumab | — | COMPLETED | 2026-03-19 | NCT06333860 |
| Bausch Health Americas, Inc. | IDP-118 Lotion | — | COMPLETED | 2026-02-06 | NCT03988439 |
| LEO Pharma | Brodalumab | Interleukin-17 Receptor A Antagonist [EPC] | COMPLETED | 2025-08-25 | NCT04306315 |
| AbbVie | Risankizumab | — | COMPLETED | 2025-01-22 | NCT05969223 |
| Bristol-Myers Squibb | Deucravacitinib | Tyrosine Kinase 2 Inhibitor [EPC] | COMPLETED | 2024-08-23 | NCT05701995 |
| Eli Lilly | Ixekizumab | Interleukin-17A Antagonist [EPC] | COMPLETED | 2024-08-08 | NCT05855967 |
| Galderma R&D | Cetaphil | — | COMPLETED | 2024-07-18 | NCT06357221 |
| Bristol-Myers Squibb | Deucravacitinib | Tyrosine Kinase 2 Inhibitor [EPC] | COMPLETED | 2024-01-11 | NCT05478499 |
| Johnson & Johnson | Guselkumab | Interleukin-23 Antagonist [EPC] | COMPLETED | 2023-09-26 | NCT04914429 |
| Organon and Co | VTAMA (tapinarof) cream, 1% | — | COMPLETED | 2023-06-30 | NCT05789576 |
| Organon and Co | VTAMA® (tapinarof) Cream 1% | — | COMPLETED | 2023-05-18 | NCT05680740 |
| AbbVie | Risankizumab | — | COMPLETED | 2023-04-20 | NCT04908475 |
| Samsung Bioepis Co., Ltd. | Humira (Adalimumab) | — | COMPLETED | 2023-04-04 | NCT05510063 |
| Almirall, S.A. | Dimethyl fumarate (DMF) standard scheme | — | COMPLETED | 2022-02-16 | NCT04263610 |
| Novartis | Secukinumab | Interleukin-17A Antagonist [EPC] | COMPLETED | 2021-11-30 | NCT03440736 |
| Novartis | Secukinumab | Interleukin-17A Antagonist [EPC] | COMPLETED | 2021-11-30 | NCT03020199 |
| Almirall, S.A. | Tildrakizumab 100 mg Solution for Injection | — | COMPLETED | 2021-11-15 | NCT04229836 |
| Sun Pharmaceutical Industries Limited | Injections of tildrakizumab | — | COMPLETED | 2021-11-02 | NCT03718299 |
| Amgen | Apremilast | Phosphodiesterase 4 Inhibitor [EPC] | COMPLETED | 2021-02-01 | NCT03774875 |
| Eli Lilly | Ixekizumab | Interleukin-17A Antagonist [EPC] | COMPLETED | 2020-07-22 | NCT03942042 |
| Mayne Pharma International Pty Ltd | Halobetasol Topical Foam | — | COMPLETED | 2019-12-30 | NCT03992261 |
| Sun Pharmaceutical Industries, Inc. | Topicort® (desoximetasone) Topical Spray, 0.25% | — | COMPLETED | 2019-11-22 | NCT02340169 |
| Eli Lilly | Ixekizumab | Interleukin-17A Antagonist [EPC] | COMPLETED | 2019-07-15 | NCT03573323 |
| LEO Pharma | Brodalumab | Interleukin-17 Receptor A Antagonist [EPC] | COMPLETED | 2019-01-24 | NCT03331835 |
| Galderma R&D | Calcitriol | Vitamin D3 Analog [EPC] | COMPLETED | 2018-05 | NCT02125279 |
| Novartis | Secukinumab | Interleukin-17A Antagonist [EPC] | COMPLETED | 2018-04-25 | NCT03055494 |
| Novartis | Secukinumab | Interleukin-17A Antagonist [EPC] | COMPLETED | 2018-03-28 | NCT02752776 |
| LEO Pharma | Xamiol® gel | — | COMPLETED | 2018-03-06 | NCT02533973 |
| Amgen | Etanercept | Tumor Necrosis Factor Blocker [EPC] | COMPLETED | 2017-08-14 | NCT02749370 |
| Novartis | Secukinumab 300 mg | — | COMPLETED | 2017-04-26 | NCT02690701 |
| Kyowa Kirin Co., Ltd. | Brodalumab 210mg SC | — | COMPLETED | 2017-01-10 | NCT04183881 |
| Primus Pharmaceuticals | DFD-01 (betamethasone dipropionate) Spray, 0.05% | — | COMPLETED | 2016-07 | NCT02749799 |
| Haus Bioceuticals | HAT1 | — | COMPLETED | 2016-06-26 | NCT03406117 |
| Novartis | Secukinumab (AIN457) | — | COMPLETED | 2016-05-02 | NCT02547714 |
| Amgen | Apremilast | Phosphodiesterase 4 Inhibitor [EPC] | COMPLETED | 2016-02-12 | NCT02425826 |
| Galderma R&D | calcitriol ointment | — | COMPLETED | 2015-11 | NCT02186665 |
| Galderma R&D | Calcitriol 3 mcg/g ointment | — | COMPLETED | 2015-11 | NCT01766440 |
| Amgen | Etanercept | Tumor Necrosis Factor Blocker [EPC] | COMPLETED | 2015-11 | NCT02274792 |
| Amgen | Etanercept via Autoinjector A | — | COMPLETED | 2014-03-04 | NCT01875991 |
| Galderma R&D | Clobex Spray | — | COMPLETED | 2013-10 | NCT01893567 |
| AbbVie (prior sponsor, Abbott) | Adalimumab | TNF | COMPLETED | 2013-09 | NCT01644396 |
| Pfizer | etanercept | Tumor Necrosis Factor Blocker [EPC] | COMPLETED | 2013-04 | NCT00992394 |
| Promius Pharma, LLC | Cloderm Cream | — | COMPLETED | 2013-03 | NCT01714544 |
| AbbVie (prior sponsor, Abbott) | Adalimumab | TNF | COMPLETED | 2012-02 | NCT01265823 |
| Piramal Enterprises Limited | TINEFCON | — | COMPLETED | 2012-02 | NCT01373567 |
| Pfizer | — | — | COMPLETED | 2011-07 | NCT01147874 |
| Pfizer | Etanercept | Tumor Necrosis Factor Blocker [EPC] | COMPLETED | 2011-04 | NCT00936065 |
| Janssen-Cilag International NV | Ustekinumab | Interleukin-12 Antagonist [EPC] | COMPLETED | 2010-11 | NCT01059773 |
| Galderma R&D | Vectical™ Ointment weekdays and Clobex® Spray weekends regimen | — | COMPLETED | 2010-03 | NCT00988637 |
| Amgen | Etanercept | Tumor Necrosis Factor Blocker [EPC] | COMPLETED | 2010-01 | NCT00791765 |
| Pfizer | Etanercept | Tumor Necrosis Factor Blocker [EPC] | COMPLETED | 2010-01 | NCT00663052 |
| Galderma R&D | clobetasol propionate spray 0.05% | — | COMPLETED | 2009-12 | NCT00881868 |
| Abbott | Adalimumab | TNF | COMPLETED | 2009-09 | NCT00735787 |
| Stiefel, a GSK Company | Olux-E Foam | — | COMPLETED | 2009-06 | NCT00852761 |
| Roche | efalizumab | — | COMPLETED | 2009-01 | NCT00669214 |
| Bristol-Myers Squibb | Deucravacitinib | Tyrosine Kinase 2 Inhibitor [EPC] | TERMINATED | 2025-04-25 | NCT06042920 |
| Johnson & Johnson | Guselkumab | Interleukin-23 Antagonist [EPC] | TERMINATED | 2023-07-28 | NCT05125679 |
| LEO Pharma | Brodalumab | Interleukin-17 Receptor A Antagonist [EPC] | TERMINATED | 2022-09-08 | NCT04533737 |
| Almirall, S.A. | Tildrakizumab | — | TERMINATED | 2020-07-31 | NCT04339595 |
| Sun Pharmaceutical Industries Limited | Halobetasol Topical Lotion | — | TERMINATED | 2019-08-12 | NCT03212963 |
| Amgen | Etanercept | Tumor Necrosis Factor Blocker [EPC] | TERMINATED | 2015-05-29 | NCT01543204 |
| Trima, Israel Pharmaceutical Products | — | — | TERMINATED | 2013-03 | NCT01149252 |
| Merck KGaA, Darmstadt, Germany | Efalizumab - anti CD11a recombinant human monoclonal antibody | — | TERMINATED | 2009-06 | NCT00739882 |
| Merck KGaA, Darmstadt, Germany | Efalizumab (Raptiva) | — | TERMINATED | 2009-05 | NCT00972543 |
| Merck KGaA, Darmstadt, Germany | Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb) | — | TERMINATED | 2009-04 | NCT00697593 |
| Kyowa Kirin Co., Ltd. | KHK4827-Active | — | WITHDRAWN | 2022-02 | NCT04614298 |
| Novartis | Secukinumab 300 mg | — | WITHDRAWN | 2021-03-24 | NCT04488185 |
| EMS | esomeprazole | — | WITHDRAWN | 2016-01 | NCT02624544 |
| Stiefel, a GSK Company | Acitretin (also called U0279) | — | WITHDRAWN | 2010-03 | NCT00832364 |
Showing 100 of 319 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| InventisBio Co., Ltd | D-2570 Tablet | — | RECRUITING | 2027-07-12 | NCT07326813 |
| InventisBio Co., Ltd | D-2570 | — | RECRUITING | 2027-07-28 | NCT07130604 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | TQH3906 capsules | — | RECRUITING | 2027-09 | NCT07724366 |
| Psoriasis Research Institute of Guangzhou | Total coumarin (TC) cream | — | RECRUITING | 2027-12-31 | NCT07426120 |
| Vanda Pharmaceuticals | Ponesimod | Sphingosine 1-phosphate Receptor Modulator [EPC] | RECRUITING | 2028-08 | NCT07362017 |
| Bristol-Myers Squibb | Deucravacitinib | Tyrosine Kinase 2 Inhibitor [EPC] | RECRUITING | 2029-01-01 | NCT04772079 |
| Bristol-Myers Squibb | Deucravacitinib | Tyrosine Kinase 2 Inhibitor [EPC] | RECRUITING | 2029-10-12 | NCT06979453 |
| Bristol-Myers Squibb | Deucravacitinib | Tyrosine Kinase 2 Inhibitor [EPC] | RECRUITING | 2031-01-16 | NCT07116967 |
| Takeda | Zasocitinib | — | RECRUITING | 2033-01-24 | NCT07250802 |
| Wooshin Labottach Co., Ltd. | — | — | RECRUITING | 2026-11 | NCT07029516 |
| Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | IBI112 | — | RECRUITING | 2026-09-30 | NCT07265284 |
| Beijing InnoCare Pharma Tech Co., Ltd. | ICP-488 Tablets | — | RECRUITING | 2026-05 | NCT06842199 |
| Shanghai Huaota Biopharmaceutical Co., Ltd. | HB0034 | — | RECRUITING | 2025-12-30 | NCT06477536 |
| UCB Biopharma SRL | bimekizumab | — | ACTIVE NOT RECRUITING | 2027-03-09 | NCT06506916 |
| Qilu Pharmaceutical Co., Ltd. | QL2106 injection | — | ACTIVE NOT RECRUITING | 2027-12-30 | NCT07511647 |
| AbbVie | Risankizumab | — | ACTIVE NOT RECRUITING | 2028-04 | NCT04862286 |
| UCB Biopharma SRL | bimekizumab | — | ACTIVE NOT RECRUITING | 2028-08-21 | NCT06425549 |
| Alumis Inc | Open-Label Envudeucitinib | — | ACTIVE NOT RECRUITING | 2028-11 | NCT06846541 |
| Takeda | TAK-279 | — | ACTIVE NOT RECRUITING | 2029-08-05 | NCT06550076 |
| Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Picankibart | — | ACTIVE NOT RECRUITING | 2026-06-07 | NCT06945107 |
| Biocad | Netakimab | — | ACTIVE NOT RECRUITING | 2026-06 | NCT06640517 |
| Celltrion | CT-P55 | — | ACTIVE NOT RECRUITING | 2026-02-18 | NCT06630559 |
| Sun Pharmaceutical Industries Limited | Tildrakizumab 100 mg | — | ACTIVE NOT RECRUITING | 2026-01-21 | NCT06611163 |
| Johnson & Johnson | JNJ-77242113 | — | ACTIVE NOT RECRUITING | 2025-11-17 | NCT06934226 |
| Sun Pharmaceutical Industries Limited | Tildrakizumab | — | ACTIVE NOT RECRUITING | 2025-04-07 | NCT03997786 |
| Janssen Pharmaceutical K.K. | JNJ-77242113 | — | ACTIVE NOT RECRUITING | 2025-01-14 | NCT06295692 |
| Johnson & Johnson | JNJ-77242113 | — | ACTIVE NOT RECRUITING | 2024-11-15 | NCT06220604 |
| Johnson & Johnson | JNJ-77242113 | — | ACTIVE NOT RECRUITING | 2024-09-17 | NCT06143878 |
| Johnson & Johnson | JNJ-77242113 | — | ACTIVE NOT RECRUITING | 2024-07-29 | NCT06095115 |
| Johnson & Johnson | JNJ-77242113 | — | ACTIVE NOT RECRUITING | 2024-06-19 | NCT06095102 |
| Johnson & Johnson | Guselkumab | Interleukin-23 Antagonist [EPC] | ACTIVE NOT RECRUITING | 2023-07-19 | NCT03451851 |
| Reistone Biopharma Company Limited | RSS0393 ointment 0.03% | — | NOT YET RECRUITING | 2027-01 | NCT07543224 |
| Hansoh BioMedical R&D Company | HS-20137 | — | NOT YET RECRUITING | 2027-03-31 | NCT06844799 |
| CSPC Ouyi Pharmaceutical Co., Ltd. | SYHX1901 | — | NOT YET RECRUITING | 2027-04-28 | NCT06943950 |
| Takeda | Zasocitinib | — | NOT YET RECRUITING | 2027-05-30 | NCT07752108 |
| Can-Fite BioPharma | piclidenoson | — | NOT YET RECRUITING | 2027-12 | NCT06643260 |
| Dermavon Holdings Limited | CMS-D001 50mg | — | NOT YET RECRUITING | 2028-02-29 | NCT07432854 |
| Bristol-Myers Squibb | Deucravacitinib | Tyrosine Kinase 2 Inhibitor [EPC] | NOT YET RECRUITING | 2030-10-31 | NCT07791199 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | SHR-1314 | — | NOT YET RECRUITING | 2026-07 | NCT06833307 |
| SFA Therapeutics | SFA002 | — | NOT YET RECRUITING | 2026-06-01 | NCT06863493 |
| Hansoh BioMedical R&D Company | HS-10374 6mg tablets | — | NOT YET RECRUITING | 2025-10-22 | NCT06672393 |
| Organon and Co | tapinarof cream, 1% | — | COMPLETED | 2026-10-14 | NCT05172726 |
| Amgen | Apremilast | Phosphodiesterase 4 Inhibitor [EPC] | COMPLETED | 2026-08-12 | NCT06088199 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | MC2-01 cream | — | COMPLETED | 2026-08-06 | NCT07357831 |
| Bristol-Myers Squibb | BMS-986165 | — | COMPLETED | 2026-07-21 | NCT04036435 |
| Takeda | Zasocitinib | — | COMPLETED | 2026-04-22 | NCT06973291 |
| UCB Biopharma SRL | Certolizumab pegol | Tumor Necrosis Factor Blocker [EPC] | COMPLETED | 2026-04-09 | NCT04123795 |
| Newsoara Biopharma Co., Ltd. | HPP737 | — | COMPLETED | 2026-04-01 | NCT07712731 |
| Livzon Pharmaceutical Group Inc. | LZM012 | — | COMPLETED | 2026-01-26 | NCT07746479 |
| Eli Lilly | Ixekizumab | Interleukin-17A Antagonist [EPC] | COMPLETED | 2026-01-08 | NCT06588283 |
| Amgen | Apremilast | Phosphodiesterase 4 Inhibitor [EPC] | COMPLETED | 2025-11-20 | NCT05565560 |
| Amgen | Apremilast | Phosphodiesterase 4 Inhibitor [EPC] | COMPLETED | 2025-10-30 | NCT04175613 |
| Takeda | TAK-279 | — | COMPLETED | 2025-10-17 | NCT06323356 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Roflumilast Cream 0.3% | — | COMPLETED | 2025-10-13 | NCT06648772 |
| Alumis Inc | Envudeucitinib | — | COMPLETED | 2025-09-23 | NCT06588738 |
| Alumis Inc | Envudeucitinib | — | COMPLETED | 2025-09-19 | NCT06586112 |
| Taizhou Mabtech Pharmaceutical Co.,Ltd | CMAB015 | — | COMPLETED | 2025-06-30 | NCT06398652 |
| Johnson & Johnson | Guselkumab | Interleukin-23 Antagonist [EPC] | COMPLETED | 2025-05-30 | NCT05272150 |
| AO GENERIUM | GNR-068 | — | COMPLETED | 2025-04-30 | NCT06488664 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI112 | — | COMPLETED | 2025-04-29 | NCT06049810 |
| Johnson & Johnson | Guselkumab | Interleukin-23 Antagonist [EPC] | COMPLETED | 2025-04-14 | NCT06039189 |
| SPH-BIOCAD (HK) Limited | Netakimab | — | COMPLETED | 2025-03-28 | NCT07008547 |
| Amgen | apremilast | Phosphodiesterase 4 Inhibitor [EPC] | COMPLETED | 2025-02-28 | NCT06122649 |
| UCB Biopharma SRL | Bimekizumab | — | COMPLETED | 2025-02-05 | NCT06011733 |
| Takeda | TAK-279 | — | COMPLETED | 2025-01-22 | NCT06088043 |
| Takeda | TAK-279 | — | COMPLETED | 2024-12-06 | NCT06108544 |
| Huabo Biopharm Co., Ltd. | HB0017 Q4W | — | COMPLETED | 2024-11-15 | NCT06477237 |
| Akeso | AK111 | — | COMPLETED | 2024-08-19 | NCT06066125 |
| Bio-Thera Solutions | BAT2306 | — | COMPLETED | 2024-05-24 | NCT05377944 |
| Sun Pharmaceutical Industries Limited | Tildrakizumab | — | COMPLETED | 2024-04-05 | NCT03897075 |
| LEO Pharma | LEO 90100 | — | COMPLETED | 2024-02-23 | NCT05919082 |
| AbbVie | Risankizumab | — | COMPLETED | 2024-02-12 | NCT04435600 |
| Arcutis Biotherapeutics, Inc. | Topical roflumilast | — | COMPLETED | 2024-01-22 | NCT04286607 |
| AbbVie | risankizumab | — | COMPLETED | 2023-11-29 | NCT03047395 |
| Akeso | AK101 injection SC | — | COMPLETED | 2023-11-24 | NCT05509361 |
| UCB Biopharma SRL | Bimekizumab | — | COMPLETED | 2023-11-14 | NCT03598790 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 608 Q2W | — | COMPLETED | 2023-10-20 | NCT05536726 |
| Newsoara Biopharma Co., Ltd. | HPP737 | — | COMPLETED | 2023-09-29 | NCT07712705 |
| Biocon Biologics Inc. | Humira 40 MG in Prefilled Syringe | — | COMPLETED | 2023-09-19 | NCT05637515 |
| Vanda Pharmaceuticals | 750 mg Imsidolimab | — | COMPLETED | 2023-08-17 | NCT05352893 |
| Celltrion | CT-P17 | — | COMPLETED | 2023-08-14 | NCT05495568 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI112 | — | COMPLETED | 2023-08-09 | NCT05645627 |
| Padagis LLC | roflumilast cream 0.3% | — | COMPLETED | 2023-08-08 | NCT05763082 |
| Boehringer Ingelheim | spesolimab | — | COMPLETED | 2023-07-17 | NCT05239039 |
| AbbVie | Risankizumab | — | COMPLETED | 2023-04-20 | NCT04713592 |
| Boehringer Ingelheim | spesolimab | — | COMPLETED | 2023-03-20 | NCT05200247 |
| Amgen | Ustekinumab | Interleukin-12 Antagonist [EPC] | COMPLETED | 2023-02-28 | NCT04761627 |
| Humanis Saglık Anonim Sirketi | Apremilast 30 mg Tablets | — | COMPLETED | 2023-02-25 | NCT06084663 |
| Biocon Biologics UK Ltd | Stelara | Interleukin-12 Antagonist [EPC] | COMPLETED | 2023-01-26 | NCT05335356 |
| Amgen | Adalimumab | TNF | COMPLETED | 2022-12-19 | NCT05073315 |
| Tianjin Hemay Pharmaceutical Co., Ltd | 60mg Hemay005 | — | COMPLETED | 2022-10-25 | NCT04839328 |
| Bio-Thera Solutions | BAT2206 | — | COMPLETED | 2022-10-12 | NCT04728360 |
| Akeso | AK101 | — | COMPLETED | 2022-09-29 | NCT05120297 |
| UCB Biopharma SRL | bimekizumab | — | COMPLETED | 2022-09-05 | NCT05020249 |
| Arcutis Biotherapeutics, Inc. | Roflumilast Foam 0.3% | — | COMPLETED | 2022-06-03 | NCT05028582 |
| Amgen | Apremilast (CC-10004) | — | COMPLETED | 2022-04-25 | NCT03701763 |
| Janssen-Cilag International NV | Guselkumab | Interleukin-23 Antagonist [EPC] | COMPLETED | 2022-03-07 | NCT03818035 |
| Samsung Bioepis Co., Ltd. | Stelara® (Ustekinumab) | — | COMPLETED | 2022-02-24 | NCT04967508 |
| Sun Pharmaceutical Industries Limited | PART 2: Double-blind Active Treatment Extension | — | COMPLETED | 2022-02-17 | NCT03897088 |
| Dong-A ST Co., Ltd. | DMB-3115 | — | COMPLETED | 2022-02-10 | NCT04785326 |
Showing 100 of 274 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Guangdong Hengrui Pharmaceutical Co., Ltd | The SHR-1139 injection | — | RECRUITING | 2026-12-31 | NCT07719530 |
| Hansoh BioMedical R&D Company | HS-20137 | — | RECRUITING | 2027-03-01 | NCT07879885 |
| InventisBio Co., Ltd | D-2570 Tablet | — | RECRUITING | 2027-08 | NCT07489885 |
| Chipscreen Biosciences, Ltd. | CS32582 capsule（low dose） | — | RECRUITING | 2027-09-18 | NCT07129382 |
| Oruka Therapeutics, Inc. | ORKA-001 | — | RECRUITING | 2030-05 | NCT07449702 |
| Beijing InnoCare Pharma Tech Co., Ltd. | ICP-332 Tablets | — | RECRUITING | 2026-10 | NCT07251998 |
| Clarent Biopharma, Inc. | CBP-0276 200mg BID | — | RECRUITING | 2026-07-31 | NCT07204639 |
| Tasly Pharmaceutical Group Co., Ltd | low dose Jiuweihuaban Pill | — | RECRUITING | 2025-10 | NCT06058546 |
| Shanghai Huaota Biopharmaceutical Co., Ltd. | HB0034 | — | RECRUITING | 2025-02-13 | NCT06231381 |
| Haisco Pharmaceutical Group Co., Ltd. | HSK44459 Cream | — | ACTIVE NOT RECRUITING | 2027-03 | NCT07623486 |
| LEO Pharma | Spesolimab | — | ACTIVE NOT RECRUITING | 2027-09-30 | NCT03886246 |
| Oruka Therapeutics, Inc. | ORKA-002 | — | ACTIVE NOT RECRUITING | 2027-10 | NCT07474792 |
| Alumis Inc | envudeucitinib | — | ACTIVE NOT RECRUITING | 2027-12-01 | NCT05739435 |
| Oruka Therapeutics, Inc. | ORKA-001 | — | ACTIVE NOT RECRUITING | 2026-10-21 | NCT07290569 |
| Oruka Therapeutics, Inc. | ORKA-001 Induction Dose | — | ACTIVE NOT RECRUITING | 2026-03-25 | NCT07090330 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | SHR-1139 Injection | — | ACTIVE NOT RECRUITING | 2025-11 | NCT06875934 |
| Haisco Pharmaceutical Group Co., Ltd. | HSK47388 | — | NOT YET RECRUITING | 2026-12-20 | NCT07158268 |
| Clarent Biopharma, Inc. | CBP-0276 capsules 100mg | — | NOT YET RECRUITING | 2027-02 | NCT07706530 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | HS-20118 | — | NOT YET RECRUITING | 2027-02-28 | NCT07765628 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | SHR-1139 | — | NOT YET RECRUITING | 2027-07 | NCT07758075 |
| Coultreon Biopharma | COL-5671-PRO | — | NOT YET RECRUITING | 2027-09-30 | NCT07914231 |
| Xantho Biotechnology Co., LTD | 5% GM-XANTHO [GM-XAN003] | — | NOT YET RECRUITING | 2027-12-31 | NCT06620692 |
| Haisco Pharmaceutical Group Co., Ltd. | HSK44459 dose level 1 | — | NOT YET RECRUITING | 2026-11-06 | NCT07150988 |
| Hansoh BioMedical R&D Company | HS-10374 6mg tablets | — | NOT YET RECRUITING | 2026-07-09 | NCT06926582 |
| Jiangsu HengRui Medicine Co., Ltd. | RSS0393 Ointment | — | NOT YET RECRUITING | 2026-02 | NCT07102888 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | TQH3906 capsules | — | COMPLETED | 2025-11-03 | NCT06542614 |
| Soligenix | Hypericin | — | COMPLETED | 2025-10-22 | NCT05442190 |
| DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | LY4100511 | — | COMPLETED | 2025-07-24 | NCT06602219 |
| Huabo Biopharm Co., Ltd. | HB0017 | — | COMPLETED | 2025-04-30 | NCT06592274 |
| Eli Lilly | LY3972406 | — | COMPLETED | 2025-04-01 | NCT06176768 |
| UCB Biopharma SRL | bimekizumab | — | COMPLETED | 2025-03-12 | NCT04718896 |
| Accro Bioscience (Suzhou) Limited | AC-201 | — | COMPLETED | 2025-03-07 | NCT06972888 |
| Akeso | AK111 | — | COMPLETED | 2024-12-11 | NCT06061471 |
| Hangzhou Highlightll Pharmaceutical Co., Ltd | TLL018 tablets | — | COMPLETED | 2024-12-01 | NCT05772520 |
| Sun Pharmaceutical Industries Limited | SCD-044_Low Dose (Dose 1) | — | COMPLETED | 2024-11-20 | NCT04566666 |
| Sanofi | SAR441566 | — | COMPLETED | 2024-11-13 | NCT06073119 |
| InventisBio Co., Ltd | D-2570 | — | COMPLETED | 2024-11-01 | NCT06278350 |
| Arctic Bioscience | HRO350 | — | COMPLETED | 2024-10-07 | NCT06125808 |
| Artax Biopharma Inc | AX-158 | — | COMPLETED | 2024-09-04 | NCT05725057 |
| Bristol-Myers Squibb | BMS-986322 | — | COMPLETED | 2024-08-06 | NCT05730725 |
| Beijing InnoCare Pharma Tech Co., Ltd. | ICP-488 Tablets | — | COMPLETED | 2024-08-05 | NCT06109818 |
| Innovent Biologics (Suzhou) Co. Ltd. | regular treatment | — | COMPLETED | 2024-07-19 | NCT05970978 |
| DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | DC-806 | — | COMPLETED | 2024-03-25 | NCT05896527 |
| GEN İlaç ve Sağlık Ürünleri A.Ş. | GN-037 | — | COMPLETED | 2024-01-04 | NCT05706870 |
| Johnson & Johnson | JNJ-77242113 | — | COMPLETED | 2023-09-29 | NCT05364554 |
| Pfizer | PF-07038124 ointment 0.01% | — | COMPLETED | 2023-07-31 | NCT05375955 |
| Alumis Inc | ESK-001 | — | COMPLETED | 2023-06-29 | NCT05600036 |
| Meiji Pharma USA Inc. | ME3183 | — | COMPLETED | 2023-05-31 | NCT05268016 |
| Huabo Biopharm Co., Ltd. | HB0017 | — | COMPLETED | 2023-05-23 | NCT05531682 |
| Johnson & Johnson | JNJ-77242113 | — | COMPLETED | 2023-03-23 | NCT05357755 |
| Akeso | AK111/Placebo | — | COMPLETED | 2023-02-03 | NCT05096364 |
| Johnson & Johnson | JNJ-77242113 | — | COMPLETED | 2022-12-15 | NCT05223868 |
| Aurigene Discovery Technologies Limited | AUR101 | — | COMPLETED | 2022-11-30 | NCT04855721 |
| UNION therapeutics | Orismilast modified release tablets | — | COMPLETED | 2022-11-24 | NCT05190419 |
| Boehringer Ingelheim | Spesolimab | — | COMPLETED | 2022-11-23 | NCT04399837 |
| Abcentra | Orticumab | — | COMPLETED | 2022-11-11 | NCT04776629 |
| Takeda | NDI-034858 study drug | — | COMPLETED | 2022-08-19 | NCT04999839 |
| Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Jaktinib | — | COMPLETED | 2022-08-15 | NCT04612699 |
| Arcutis Biotherapeutics, Inc. | ARQ-151 cream 0.3% | — | COMPLETED | 2022-05-11 | NCT04746911 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI112 dose 2 | — | COMPLETED | 2022-03-25 | NCT05003531 |
| Akeso | AK101 | — | COMPLETED | 2022-03-03 | NCT04173637 |
| Aldeyra Therapeutics, Inc. | ADX-629 | — | COMPLETED | 2022-01-21 | NCT04908514 |
| Arcutis Biotherapeutics, Inc. | ARQ-151 cream 0.3% | — | COMPLETED | 2022-01-12 | NCT04655313 |
| Newsoara Biopharma Co., Ltd. | HPP737 20mg | — | COMPLETED | 2021-12-20 | NCT07707141 |
| Pfizer | PF-07038124 ointment | — | COMPLETED | 2021-08-18 | NCT04664153 |
| BioMimetix JV, LLC | BMX-010 | — | COMPLETED | 2021-07-24 | NCT03381625 |
| Evelo Biosciences, Inc. | EDP1815 | — | COMPLETED | 2021-07-02 | NCT04603027 |
| Boehringer Ingelheim | BI 25 mg (fasted) | — | COMPLETED | 2021-05-06 | NCT03635099 |
| Pfizer | PF-06700841 | — | COMPLETED | 2021-04-20 | NCT03850483 |
| Aurigene Discovery Technologies Limited | AUR101 | — | COMPLETED | 2021-03-20 | NCT04207801 |
| Vanda Pharmaceuticals | Imsidolimab | — | COMPLETED | 2021-01-20 | NCT03619902 |
| Therapeutics, Inc. | 188-0551 Spray | — | COMPLETED | 2021-01-20 | NCT04080206 |
| Syntrix Biosystems, Inc. | LD-Aminopterin oral capsule | — | COMPLETED | 2021-01-11 | NCT03431974 |
| Tianjin Hemay Pharmaceutical Co., Ltd | 15mg Hemay005 | — | COMPLETED | 2020-10-12 | NCT04102241 |
| Arcutis Biotherapeutics, Inc. | Roflumilast | Phosphodiesterase 4 Inhibitor [EPC] | COMPLETED | 2020-10-08 | NCT03764475 |
| Boehringer Ingelheim | Spesolimab | — | COMPLETED | 2020-09-23 | NCT03782792 |
| Arcutis Biotherapeutics, Inc. | Roflumilast foam 0.3% | — | COMPLETED | 2020-09-23 | NCT04128007 |
| Jiangsu HengRui Medicine Co., Ltd. | SHR-1314 | — | COMPLETED | 2020-08-31 | NCT03463187 |
| Therapeutics, Inc. | UHE-105 | — | COMPLETED | 2020-06-15 | NCT04243486 |
| Pfizer | PF-06826647 | — | COMPLETED | 2020-05-21 | NCT03895372 |
| Roche | KPL-716 | — | COMPLETED | 2020-04-01 | NCT03858634 |
| Dr. Reddy's Laboratories Limited | PPC-06 400 mg QD | — | COMPLETED | 2020-03-30 | NCT03421197 |
| Akros Pharma Inc. | JTE-451 Tablets | — | COMPLETED | 2020-03-13 | NCT03832738 |
| Novartis | — | — | COMPLETED | 2020-01-28 | NCT03553823 |
| Organon and Co | Tapinarof cream, 1% | — | COMPLETED | 2020-01-09 | NCT04042103 |
| Durect | DUR-928 Topical Solution | — | COMPLETED | 2019-11-11 | NCT03837743 |
| Akeso | AK101 | — | COMPLETED | 2019-10-31 | NCT04172233 |
| Bond Avillion 2 Development LP | M1095 (Sonelokimab) | — | COMPLETED | 2019-06-20 | NCT03384745 |
| MetrioPharm AG | MP1032 | — | COMPLETED | 2019-06-12 | NCT03706209 |
| Arcutis Biotherapeutics, Inc. | Roflumilast Cream 0.3% | — | COMPLETED | 2019-05-29 | NCT03638258 |
| Affibody | ABY-035 | — | COMPLETED | 2019-03-27 | NCT03591887 |
| UCB Biopharma SRL | Bimekizumab | — | COMPLETED | 2019-03-06 | NCT03230292 |
| Kadmon Corporation, LLC | Belumosudil | — | COMPLETED | 2019-02-13 | NCT02852967 |
| Sienna Biopharmaceuticals | SNA-120 | — | COMPLETED | 2018-11-21 | NCT03448081 |
| Vyne Therapeutics Inc. | 5 mg Serlopitant Tablets | — | COMPLETED | 2018-10-23 | NCT03343639 |
| UCB Biopharma SRL | Bimekizumab | — | COMPLETED | 2018-09-25 | NCT03010527 |
| Sienna Biopharmaceuticals | SNA-120 | — | COMPLETED | 2018-09-10 | NCT03322137 |
| AbbVie | Risankizumab | — | COMPLETED | 2018-09-04 | NCT02203851 |
| MC2 Therapeutics | MC2-01 Cream | — | COMPLETED | 2018-08-04 | NCT03462927 |
| Boehringer Ingelheim | Spesolimab (low dose) | — | COMPLETED | 2018-07-12 | NCT03135548 |
Showing 100 of 189 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Huabo Biopharm Co., Ltd. | HB0017 Injection | — | RECRUITING | 2026-12-31 | NCT07920861 |
| HighsLab Therapeutics Inc. | HL40626S tablets | — | RECRUITING | 2027-02 | NCT07736586 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | HRS-4139 Tablet | — | RECRUITING | 2027-03 | NCT07802964 |
| Zealand Pharma | ZP9830 | — | RECRUITING | 2027-04 | NCT07733089 |
| Seismic Therapeutic AU Pty Ltd | S-4321 | — | RECRUITING | 2027-09 | NCT07455578 |
| Merck | MK-8644 | — | RECRUITING | 2027-12-13 | NCT07850310 |
| UCB Biopharma SRL | Bimekizumab | — | RECRUITING | 2027-12-31 | NCT06888193 |
| Chong Kun Dang Pharmaceutical | SKYRIZI | Interleukin-23 Antagonist [EPC] | RECRUITING | 2026-09-30 | NCT07258745 |
| Usynova Pharmaceuticals Ltd. | UA026 | — | RECRUITING | 2026-03-01 | NCT07038720 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | HS-20118 | — | RECRUITING | 2026-03 | NCT07033234 |
| LAPIX Therapeutics Inc. | LPX-TI641 | — | RECRUITING | 2026-01-15 | NCT06982352 |
| Ganzhou Hemay Pharmaceutical Co., Ltd | Hemay005 | — | RECRUITING | 2025-12-10 | NCT06376474 |
| SFA Therapeutics | SFA002 | — | RECRUITING | 2025-07-30 | NCT05642182 |
| AbbVie | ABBV-547 | — | ACTIVE NOT RECRUITING | 2028-05 | NCT07232004 |
| Atridia Pty Ltd. | SHR-1139 Injection | — | ACTIVE NOT RECRUITING | 2026-09-30 | NCT07078695 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | TQH2929 Injection | — | ACTIVE NOT RECRUITING | 2025-07-08 | NCT06433531 |
| Amgen | Apremilast XR | — | NOT YET RECRUITING | 2027-01-10 | NCT07908641 |
| Shanghai Peptidstar Therapeutics Limited | HCXT-2001 Tablets | — | NOT YET RECRUITING | 2026-11-10 | NCT07792928 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | HS-20118 | — | COMPLETED | 2026-07-14 | NCT06846710 |
| Ascletis Pharma (China) Co., Limited | ASC50 tablets or matching placebo | — | COMPLETED | 2026-07-01 | NCT07024602 |
| Taizhou Mabtech Pharmaceutical Co.,Ltd | Secukinumab 150mg s.c. | — | COMPLETED | 2026-06-12 | NCT07254325 |
| Arcutis Biotherapeutics, Inc. | ARQ-154 Foam 0.3% | — | COMPLETED | 2026-04-30 | NCT07340216 |
| Sun Pharmaceutical Industries, Inc. | Tapinarof Cream, 1% | — | COMPLETED | 2026-03-18 | NCT07546214 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | SHR-1139 Injections | — | COMPLETED | 2025-11-28 | NCT07051538 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | CAN10 | — | COMPLETED | 2025-11-10 | NCT06143371 |
| Biocon Biologics UK Ltd | Bmab 1200 (Biosimilar Ustekinumab) | — | COMPLETED | 2025-07-12 | NCT06738277 |
| selectION Therapeutics GmbH | si-544 | — | COMPLETED | 2025-06-23 | NCT06191042 |
| Hansoh BioMedical R&D Company | HS-10374 tablets | — | COMPLETED | 2025-06-17 | NCT07181343 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | TQH3906 capsule | — | COMPLETED | 2025-04-27 | NCT06230588 |
| Ganzhou Hemay Pharmaceutical Co., Ltd | Hemay005 | — | COMPLETED | 2025-04-16 | NCT06380153 |
| Boehringer Ingelheim | BI 765250 | — | COMPLETED | 2025-02-24 | NCT05728489 |
| Ganzhou Hemay Pharmaceutical Co., Ltd | Hemay005 | — | COMPLETED | 2025-01-20 | NCT06610890 |
| Ganzhou Hemay Pharmaceutical Co., Ltd | Hemay005 | — | COMPLETED | 2024-09-30 | NCT06610903 |
| BioRay Pharmaceutical Co., Ltd. | BR201 | — | COMPLETED | 2024-08-19 | NCT06126718 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | TQH2929 injection | — | COMPLETED | 2024-08-02 | NCT06156280 |
| Arxx Therapeutics | AX-202 | — | COMPLETED | 2024-07-31 | NCT05965089 |
| Ono Pharmaceutical Co., Ltd. | ONO-4685 | — | COMPLETED | 2024-07-18 | NCT05332704 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | SHR-1314 | — | COMPLETED | 2024-05-13 | NCT06182384 |
| Johnson & Johnson | Ustekinumab | Interleukin-12 Antagonist [EPC] | COMPLETED | 2024-01-26 | NCT05252533 |
| Shanghai Huaota Biopharmaceutical Co., Ltd. | HB0034 | — | COMPLETED | 2023-11-15 | NCT05512598 |
| Hangzhou Highlightll Pharmaceutical Co., Ltd | TLL018 tablets | — | COMPLETED | 2023-08-30 | NCT05342428 |
| Hangzhou Yirui Pharmaceutical Technology Co., Ltd | YR001 Dose A on low body surface area | — | COMPLETED | 2023-08-14 | NCT05718921 |
| Taizhou Mabtech Pharmaceutical Co.,Ltd | Secukinumab | Interleukin-17A Antagonist [EPC] | COMPLETED | 2023-07-03 | NCT05734482 |
| UCB Biopharma SRL | Pharmacokinetics of certolizumab pegol | — | COMPLETED | 2023-05-23 | NCT04163016 |
| Bio-Thera Solutions | BAT2306 | — | COMPLETED | 2023-05-03 | NCT04711343 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | HS-10374 tablets | — | COMPLETED | 2023-03-24 | NCT06033742 |
| Sanofi | SAR441566 | — | COMPLETED | 2023-02-09 | NCT05453942 |
| Pyramid Biosciences | PBI-100 Topical Cream | — | COMPLETED | 2023-01-12 | NCT05514353 |
| Eli Lilly | LY3361237 | — | COMPLETED | 2022-11-29 | NCT04975295 |
| OrchestratePharma GmbH | Fexofenadine Hydrochloride Topical Lotion 1% (OP2101) | — | COMPLETED | 2022-10-16 | NCT05461456 |
| Longevity Inc. | Ethoximod | — | COMPLETED | 2022-09-20 | NCT06361212 |
| DelArrivo, Inc. | DLX105-DMP | — | COMPLETED | 2022-09-01 | NCT04203433 |
| DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | DC-806 | — | COMPLETED | 2022-08-23 | NCT06808815 |
| Huabo Biopharm Co., Ltd. | HB0017 150mg or matching placebo | — | COMPLETED | 2022-05-31 | NCT05442788 |
| Paracrine Therapeutics Dermatology Pte. Ltd. | Exosome ointment | — | COMPLETED | 2022-04-05 | NCT05523011 |
| Alvotech Swiss AG | Stelara PFS | — | COMPLETED | 2022-03-19 | NCT04744363 |
| Evelo Biosciences, Inc. | EDP1867 | — | COMPLETED | 2022-02-28 | NCT04927195 |
| BioFactura Australia Pty Ltd. | BFI-751 | — | COMPLETED | 2021-12-08 | NCT04843631 |
| Evelo Biosciences, Inc. | EDP1815 | — | COMPLETED | 2021-10-29 | NCT03733353 |
| GSK | GSK2982772 | — | COMPLETED | 2021-09-13 | NCT04316585 |
| Tianjin Hemay Pharmaceutical Co., Ltd | Hemay005 | — | COMPLETED | 2021-08-01 | NCT04837235 |
| Nektar Therapeutics | LY3471851 | — | COMPLETED | 2021-07-21 | NCT04119557 |
| Galapagos NV | GLPG3667 | — | COMPLETED | 2021-05-04 | NCT04594928 |
| Bio-Thera Solutions | BAT2206 | — | COMPLETED | 2021-04-19 | NCT04371185 |
| AbbVie | ABBV-157 | — | COMPLETED | 2021-04-13 | NCT03922607 |
| Arcutis Biotherapeutics, Inc. | ARQ-151- cream 0.3% | — | COMPLETED | 2021-03-25 | NCT04279119 |
| PharmaEssentia | KX01 0.01% (0.1 mg/g) | — | COMPLETED | 2021-03-10 | NCT05522816 |
| Galapagos NV | GLPG3970 oral solution | — | COMPLETED | 2021-03-05 | NCT04106297 |
| Akeso | AK111 | — | COMPLETED | 2021-03-02 | NCT05504317 |
| Affibody | ABY-035/AFO2 | — | COMPLETED | 2020-09-22 | NCT03580278 |
| Bayer | BAY1834845 | — | COMPLETED | 2020-09-16 | NCT03493269 |
| Fresenius Kabi SwissBioSim GmbH | 40 mg MSB11022 | — | COMPLETED | 2020-03-17 | NCT04018599 |
| Boston Pharmaceuticals | BOS-475 | — | COMPLETED | 2020-03-06 | NCT04221906 |
| Boston Pharmaceuticals | BOS-475 | — | COMPLETED | 2020-01-28 | NCT03960450 |
| Evelo Biosciences, Inc. | Placebo oral capsule | — | COMPLETED | 2020-01-03 | NCT03542994 |
| NKGen Biotech, Inc. | Study Product: SNK01 | — | COMPLETED | 2019-12-03 | NCT03894579 |
| LEO Pharma | Microarray patch A | — | COMPLETED | 2019-10-29 | NCT03898583 |
| Eli Lilly | Drug Cocktail | — | COMPLETED | 2019-10-28 | NCT03718884 |
| Sun Pharmaceutical Industries, Inc. | Topical TA-102 A | — | COMPLETED | 2019-10-24 | NCT03645499 |
| Akesobio Australia Pty Ltd | AK111 or Placebo | — | COMPLETED | 2019-09-09 | NCT03622021 |
| Eli Lilly | Ixekizumab | Interleukin-17A Antagonist [EPC] | COMPLETED | 2019-05-14 | NCT03073213 |
| Bristol-Myers Squibb | BMS-986165 | — | COMPLETED | 2019-05-01 | NCT03873415 |
| Bristol-Myers Squibb | CC-90006 | — | COMPLETED | 2019-04-26 | NCT03337022 |
| Palobiofarma SL | PBF-1650 oral capsules | — | COMPLETED | 2019-03-30 | NCT03798236 |
| Pfizer | PF-06763809 | — | COMPLETED | 2019-03-20 | NCT03469336 |
| Eli Lilly | LY3041658 | — | COMPLETED | 2019-03-19 | NCT02896868 |
| Sun Pharmaceutical Industries, Inc. | Betamethasone Scalp Suspension 0.064%;0.0005% | — | COMPLETED | 2019-03-15 | NCT03880357 |
| LEO Pharma | LEO 134310 | — | COMPLETED | 2019-02-01 | NCT03669757 |
| Pfizer | PF-06826647 tablet | — | COMPLETED | 2019-01-25 | NCT03210961 |
| One World Cannabis Ltd. | OWC MGC cream | — | COMPLETED | 2019-01-25 | NCT02976779 |
| Eli Lilly | LY3316531 - IV | — | COMPLETED | 2018-12-24 | NCT03418493 |
| UCB Biopharma SRL | UCB0159 | — | COMPLETED | 2018-12-08 | NCT07849894 |
| Boehringer Ingelheim | BI 730357 | — | COMPLETED | 2018-08-24 | NCT03279978 |
| Mayne Pharma International Pty Ltd | Calcipotriene 0.005% Foam | — | COMPLETED | 2018-08 | NCT01582932 |
| Tianjin Hemay Bio-Tech Co., Ltd | Hemay005 | — | COMPLETED | 2018-06 | NCT03007810 |
| Bristol-Myers Squibb | BMS-986165 | — | COMPLETED | 2018-05-04 | NCT03419910 |
| GSK | GSK2831781 | — | COMPLETED | 2018-03-07 | NCT02195349 |
| Prothena Biosciences Limited | PRX003 | — | COMPLETED | 2018-02-28 | NCT02630901 |
| LEO Pharma | LEO 90100 foam | — | COMPLETED | 2018-02-20 | NCT03442244 |
| Novan, Inc. | SB414 6% | — | COMPLETED | 2018-01-31 | NCT03445013 |
Precision Medicine Biomarkers
All biomarkers →Biomarkers used for patient selection in Psoriasis
Novel Psoriasis Drugs by Company (New molecular entities)
1 company has an FDA-approved novel drug for Psoriasis.
Reformulations (3 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Psoriasis Drug Targets
Molecular targets of approved and investigational Psoriasis drugs — 1 target tracked.
Generic Drugs (8 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs